Completed PHASE1 INTERVENTIONAL 1-arm NCT03437265

A Pharmacokinetic Study of PLENVU® in Healthy Subjects (PKPU)

Sponsor: Norgine

Interventions PLENVU powder for oral solution

Updated 9 times since 2018 Last updated: Nov 7, 2023 Started: Sep 3, 2020 Primary completion: Oct 5, 2020 Completion: Oct 5, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pharmacokinetic and is currently completed. Norgine leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2021 — Dec 2023 [monthly]

Completed PHASE1
Oct 2021 — Dec 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed

▶ Show 4 earlier versions

Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE1
Mar 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Mar 2020 [monthly]

Not Yet Recruiting PHASE1
Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Norgine
Quotient Sciences

Data source: Norgine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom